IRadimed
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average or in the bottom third on momentum — the strategy is out of it.
- Signal has read SELL for 4 months.
- Its last 9 Sell calls were actually followed by a +10% average gain three months out - this one has bounced back faster than the signal expected.
- Recent price momentum is +0.3% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has risen to 4.6% of float.
- Analyst tilt is Hold.
- Price is above its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-22 02:27 UTC
Data coverage: 5 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation D-
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 43.3x | Better than 12% |
| Forward P/E | 38.2x | Better than 11% |
| Price / Sales | 12.2x | Better than 9% |
| P/E vs own 5-yr range | 69th pctl | Better than 39% |
Growth A-
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | 16.3% | Better than 78% |
| Net income CAGR (3Y) | 20.6% | Better than 73% |
| Free cash flow CAGR (3Y) | 26.5% | Better than 71% |
Profitability A+
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 76.7% | Better than 88% |
| Operating margin | 31.2% | Better than 90% |
| Net margin | 26.8% | Better than 86% |
| Return on equity | 24.8% | Better than 83% |
| Return on invested capital | 23.0% | Better than 93% |
Momentum B-
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -2.8% | Better than 67% |
| 6-month return | -7.1% | Better than 44% |
| 12-month return (ex latest month) | -3.0% | Better than 31% |
| Distance below 52-week high | 24.2% | Better than 52% |
Financial Health A
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 8.0x | Better than 92% |
| Debt to assets | 0.0% | Better than 100% |
| Free cash flow / net income | 73.5% | Better than 23% |
Analyst View N/A
What the Street thinks: share of Buy ratings and upside to the average target.
Not enough data to grade this factor.
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 81.26
- Open
- 80.61
- Day range
- 80.61 - 82.11
- Avg price
- 81.29
- Volume
- 101.30K
- Turnover
- 8.24M
- Turnover ratei
- 1.22%
- Volume ratioi
- 1.07
- Amplitudei
- 1.84%
- 52-week rangei
- 76.17 - 106.95
Valuation
- P/Ei
- 46.30
- P/E (TTM)i
- 43.33
- P/Bi
- 9.73
- EPSi
- 1.75
- Book value / shi
- 8.32
- Net profit
- 22.38M
- Net assets
- 106.45M
Share structure
- Market cap
- 1.04B
- Float capi
- 675.01M
- Shares out
- 12.79M
- Float sharesi
- 8.33M
Dividend & listing
- Div yield (TTM)i
- 0.95%
- Dividend (TTM)
- 0.77
- Listing date
- --
24.2% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-3.12M net over the window
Short interest
- Shares short
- 590.05K
- % of floati
- 4.61%
- Days to coveri
- 5.10
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of IRadimed (IRMD)?
IRadimed last traded at 81.02. This page shows a periodic quote snapshot. Check the displayed quote time.
What is IRadimed's market cap?
About 1.04B.
What is the P/E ratio of IRadimed?
The trailing twelve-month P/E is 43.33, above its own 5-year average of 43.22 — toward the top of its historical range (68.87% percentile). See the Valuation tab for the full history.
Does IRadimed pay a dividend?
Yes. The trailing dividend yield is 0.95%. The 2025 payout was up 162.2% from 2024. See the Dividends tab for the full payment history.
Is IRadimed a buy according to analysts?
The consensus of 1 analysts is a Hold rating, with an average 12-month price target of 120.00, which implies 48.1% upside from the current price. This is not investment advice.
What is IRadimed's StockVane Quant Rating?
The StockVane Momentum strategy currently rates IRadimed a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
IRadimed discussion 0 comments